CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 279 enrolled
Drug / intervention
ACE (AI-Cirrhosis-ECG) 2.0device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05782283
NCT05782283N/ACompleted
CompareCT.gov

Early Detection of Advanced Liver Disease Via Artificial Intelligence-Enabled Electrocardiogram (Advance): A Pragmatic, Cluster-Randomized Clinical Trial

Mayo Clinic·interventional·Posted Mar 23, 2023·Updated Sep 24, 2025

In Brief

A clinical study evaluating ACE (AI-Cirrhosis-ECG) 2.0 for Cirrhosis. Completed, enrolled 279 participants across 1 site.

Detailed Summary

The overall objectives of this study are to determine the effectiveness of ACE 2.0 model in early detection of advanced liver fibrosis, and to determine the acceptance and barriers for use of an AI-enabled algorithm for prediction of liver disease in primary care.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCirrhosis
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedMar 23, 2023
Enrollment StartApr 18, 2023
Primary CompletionSep 1, 2025
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 3.3 years ago

Interventions

ACE (AI-Cirrhosis-ECG) 2.0device

An electrocardiogram (ECG) based artificial intelligence (AI) powered tool for detection of undiagnosed cirrhosis in primary care practices. And email alert is sent to providers which will display whether the ACE 2.0 result is positive or negative for the likelihood of advanced liver disease.